Vivance Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
148
- Latest Deal Type
-
Later Stage VC
- Investors
-
16
Vivance General Information
Description
Developer of ultraportable dialysis devices designed for chronic kidney disease management. The company's ultraportable dialysis device uses sorbent technology that regenerates and reconstitutes used dialysis fluid into fresh fluid and provides the necessary clearance of uremic toxins, enabling patients to reduce treatment burden through a more convenient dialysis experience.
Contact Information
Website
www.vivance.comCorporate Office
- 3 Tuas Lane
- Singapore, 638612
- Singapore
Corporate Office
- 3 Tuas Lane
- Singapore, 638612
- Singapore
Vivance Timeline
Vivance Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 01-Jan-2026 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 01-Jan-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B1) | 13-Sep-2023 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A1) | 13-Dec-2019 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series A) | 03-May-2017 | $8.72M | $19.9M | Completed | Generating Revenue | |
| 1. Corporate | 01-Dec-2016 | $11.2M | $11.2M | Completed | Generating Revenue |
Vivance Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 2,323,363 | $3.75 | $3.75 | 1x | $3.75 | 7.08% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vivance Comparisons
Industry
Financing
Details
Vivance Competitors (7)
One of Vivance’s 7 competitors is Physidia, a Private Equity-Backed company based in Saint-Barthelemy d'Anjou, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Physidia | Private Equity-Backed | Saint-Barthelemy d'Anjou, France | ||||
| PENTAX Medical | Corporation | Tokyo, Japan | ||||
| Baxter International | Corporation | Deerfield, IL | ||||
| Kamu | Venture Capital-Backed | Helsinki, Finland | ||||
| Quanta Dialysis Technologies | Venture Capital-Backed | Warwick, United Kingdom |
Vivance Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vivance Patents
Vivance Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026147348-A1 | A dialysis apparatus | Pending | 31-Dec-2024 | ||
| WO-2026084652-A1 | Metal-organic frameworks for use in preventing or treating hyperphosphatemia | Pending | 18-Oct-2024 | ||
| WO-2026071972-A1 | Activated carbon adsorbent | Pending | 27-Sep-2024 | ||
| AU-2025201315-A1 | Peritoneal dialysis methods | Pending | 23-Feb-2024 | ||
| US-20250269100-A1 | Peritoneal dialysis methods | Pending | 23-Feb-2024 | A61K31/70 |
Vivance Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vivance Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Economic Development Innovations Singapore | PE/Buyout | Minority | ||
| Eckuity | Growth/Expansion | Minority | ||
| Enterprise Singapore | Government | Minority | ||
| Fidem Investment | Venture Capital | Minority | ||
| Greenoaks | Venture Capital | Minority |
Vivance Investments (1)
Vivance’s most recent deal was a Later Stage VC with Diality for . The deal was made on 31-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Diality | 31-Mar-2022 | Later Stage VC | Therapeutic Devices |
Vivance FAQs
-
When was Vivance founded?
Vivance was founded in 2007.
-
Where is Vivance headquartered?
Vivance is headquartered in Singapore, Singapore.
-
What is the size of Vivance?
Vivance has 148 total employees.
-
What industry is Vivance in?
Vivance’s primary industry is Therapeutic Devices.
-
Is Vivance a private or public company?
Vivance is a Private company.
-
What is Vivance’s current revenue?
The current revenue for Vivance is .
-
How much funding has Vivance raised over time?
Vivance has raised $84.7M.
-
Who are Vivance’s investors?
Economic Development Innovations Singapore, Eckuity, Enterprise Singapore, Fidem Investment, and Greenoaks are 5 of 16 investors who have invested in Vivance.
-
Who are Vivance’s competitors?
Physidia, PENTAX Medical, Baxter International, Kamu, and Quanta Dialysis Technologies are some of the 7 competitors of Vivance.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
